PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Inhibits progression via regulation of the PTEN/AKT signaling pathway in vivo and in vitro [PMID: 37429502]
Methanol extract and ethyl acetate fractions showed anti-oxidative and anti-inflammatory activities in vitro (RAW264.7 macrophages) and in vivo (acute rat lung injury model) [PMID: 25787301]
Extract and active compound diosmetin improved atopic dermatitis in a DNCB-induced murine model and human keratinocytes [PMID: 35955819]
Inulin-type fructan (LCPS) reduced body weight gain, liver weight, total cholesterol, and triglycerides in high fat diet-induced mice [PMID: 32475601]
Aqueous extract affected colonic epithelial proliferation and apoptosis in DMH-induced rats [PMID: 24311860]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 24444893 (2014) — Chemical constituents of Lobelia chinensis. · Fitoterapia
- 2.PMID: 24636059 (2014) — Lobelia chinensis: chemical constituents and anticancer activity perspective. · Chinese journal of natural medicines
- 3.PMID: 37429502 (2024) — Lobelia chinensis Lour inhibits the progression of hepatocellular carcinoma via the regulation of the PTEN/AKT signaling pathway in vivo and in vitro. · Journal of ethnopharmacology
- 4.PMID: 32265717 (2020) — Network Pharmacology-Based Dissection of the Anti-diabetic Mechanism of Lobelia chinensis. · Frontiers in pharmacology
- 5.PMID: 35955819 (2022) — Lobelia chinensis Extract and Its Active Compound, Diosmetin, Improve Atopic Dermatitis by Reinforcing Skin Barrier Function through SPINK5/LEKTI Regulation.